Drug Trial Radar · NCT07724340
A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jun 19, 2026
Primary completion
Feb 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Antag TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if AT673 contributes to additional weight loss and glycemic control when given with semaglutide in participants with overweight/obesity and type 2 diabetes. The main questions it aims to answer are: * To compare the effect on body weight of two doses of AT673 once-weekly versus matched placebo when concurrently administered with semaglutide once-weekly * To evaluate the effect of AT673 on glycated hemoglobin (HbA1c) * To compare the safety and tolerability of AT673 versus matched placebo when concurrently administered with semaglutide
Conditions
- Adults With Overweight/Obesity and Type 2 Diabetes
Interventions
AT673 low doseDrug
low dose
AT673 high doseDrug
high dose
PlaceboDrug
matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Body weightTime frame: 13 weeks
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
CenExel Phoenix
Chandler, Arizona
CenExel Anaheim
Anaheim, California
CenExel Hollywood
Hollywood, Florida
CenExel Tampa
Tampa, Florida
CenExel Atlanta
Atlanta, Georgia
CenExel Decatur
Decatur, Georgia
CenExel Savannah
Savannah, Georgia
CenExel SLC
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.